The anthracyclines: When good things go bad Giorgio MinottiNarine Sarvazyan Editorial 03 May 2007 Pages: 53 - 55
Role of anthracyclines in the era of targeted therapy Hernán Cortés-FunesCyntia Coronado OriginalPaper 25 April 2007 Pages: 56 - 60
Pathophysiology and diagnosis of cancer drug induced cardiomyopathy Christian ZuppingerFrancesco TimolatiThomas M. Suter OriginalPaper 26 April 2007 Pages: 61 - 66
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes Luca GianniEmanuela SalvatorelliGiorgio Minotti OriginalPaper 19 April 2007 Pages: 67 - 71
Ongoing phase I and II studies of novel anthracyclines Cristiana SessaOlga ValotaCristina Geroni OriginalPaper 22 May 2007 Pages: 75 - 79
An introduction to the metabolic determinants of anthracycline cardiotoxicity Pierantonio MennaStefania RecalcatiGiorgio Minotti OriginalPaper 25 April 2007 Pages: 80 - 85
Anthracycline-induced phospholipase A2 inhibition Luther SwiftJane McHowatNarine Sarvazyan OriginalPaper 19 April 2007 Pages: 86 - 91
Antioxidant defense against anthracycline cardiotoxicity by metallothionein Y. James Kang OriginalPaper 19 April 2007 Pages: 95 - 100
Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis Kendall B. Wallace OriginalPaper 19 April 2007 Pages: 101 - 107
Role of mtDNA lesions in anthracycline cardiotoxicity Dirk LebrechtUlrich A. Walker OriginalPaper 25 April 2007 Pages: 108 - 113
Molecular and cellular mechanisms of anthracycline cardiotoxicity Billy ChenXuyang PengDouglas B. Sawyer OriginalPaper 03 May 2007 Pages: 114 - 121
Anthracycline cardiotoxicity in long-term survivors of childhood cancer Rebecca E. ScullySteven E. Lipshultz OriginalPaper 19 April 2007 Pages: 122 - 128
Genotyping the risk of anthracycline-induced cardiotoxicity Shiwei DengLeszek Wojnowski Original Paper 19 April 2007 Pages: 129 - 134
Long-term and short-term models for studying anthracycline cardiotoxicity and protectors Jacques Robert Original Paper 17 April 2007 Pages: 135 - 139
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Brian B. HasinoffEugene H. Herman OriginalPaper 25 April 2007 Pages: 140 - 144
New iron chelators in anthracycline-induced cardiotoxicity Helena KaiserováTomáš ŠimůnekAalt Bast Original Paper 19 April 2007 Pages: 145 - 150
Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries Seppo W. LangerPeter Buhl JensenMaxwell Sehested OriginalPaper 25 April 2007 Pages: 151 - 153
Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials Aalt BastGuido R. M. M. HaenenWim J. F. Van der Vijgh OriginalPaper Open access 26 May 2007 Pages: 154 - 159
Novel antioxidants in anthracycline cardiotoxicity Kálmán HidegTamás Kálai OriginalPaper 03 May 2007 Pages: 160 - 164
